Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vabomere in Children With Complicated Urinary Tract Infection
NCT06672978Phase 2Active, not recruiting
- Sponsor
- Rempex Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of meropenem + vaborbactam in complicated urinary tract infection (cUTI) and acute pyelonephritis (3 cohorts), sponsored by Rempex Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events up to 28 days. Started Jun 2025; status: active, not recruiting.
02
Drugs
meropenem + vaborbactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT06672978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672978.